| Drug General Information |
| Drug ID |
D0W9KO
|
| Former ID |
DNC011184
|
| Drug Name |
4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H13N3O2
|
| Canonical SMILES |
C1=CC(=C(C=C1CNC2=CC3=C(C=C2)C=NN3)O)O
|
| InChI |
1S/C14H13N3O2/c18-13-4-1-9(5-14(13)19)7-15-11-3-2-10-8-16-17-12(10)6-11/h1-6,8,15,18-19H,7H2,(H,16,17)
|
| InChIKey |
FOCLURCEJLBSGE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Insulin receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Insulin-like growth factor I receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Adherens junction
|
|
Insulin signaling pathway
|
|
Ovarian steroidogenesis
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorptionhsa04014:Ras signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
PI3 kinase pathwayP00032:Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Pathway Interaction Database
|
Insulin Pathway
|
|
Signaling events mediated by PTP1B
|
|
Signaling events mediated by TCPTP
|
|
Insulin-mediated glucose transporter_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
PathWhiz Pathway
|
Insulin Signalling
|
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
IRS activation
|
|
Signal attenuation
|
|
Insulin receptor signalling cascade
|
|
Insulin receptor recyclingR-HSA-2428928:IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1R
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Insulin Signaling
|
|
Nanoparticle triggered autophagic cell death
|
|
AGE/RAGE pathway
|
|
Signaling by Insulin receptor
|
|
Folate Metabolism
|
|
Type II diabetes mellitus
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
AMPK SignalingWP615:Senescence and Autophagy in Cancer
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | Eur J Pharmacol. 2007 May 7;562(1-2):1-11. Epub 2007 Feb 3.ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. |
|---|
